Skip to main content
IVAInventiva S.A. - American DeposSell4.7·$3.22
SellModerate Confidence
Investment thesis

Inventiva is a speculative pre-revenue biotech burning cash heavily, with quality below the 4.0 floor, a confirmed downtrend and material insider selling; the analyst target in the data was rejected as implausible, so upside is unproven.

Thesis pillars

  • Quality Below Floor↑Improving
  • Heavy Cash Burn→Stable
  • Confirmed Downtrend↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 14, 2026

Full reasoning →

Open full analysis

Inventiva S.A. - American Depos (IVA) Stock Analysis

Falling Knife setup

SellVALUE-TRAP 2/5ShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $3.22: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a... Read more

$3.22+29.8% Upside to targetScore 4.7/10#189 of 240 Biotechnology
QualityF-score3 / 9FCF yield-15.08%
Stop $3.01Resistance target $4.18A.R:R 0.0:1
Analyst consensus$14.42+347.7%12 analysts with price targets
$4.18Resistance target
$3.22price
$14.42mean
$26

Sell if holding. Engine safety override at $3.22: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 4.7/10, moderate confidence.

Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 134d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 5, 2026

Recent Developments — Inventiva S.A. - American Depos

Latest item Nov 5, 2026 · Generated 2026-11-18T12:07:47Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Apr 1, 2027134d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
DATA_ISSUE: analyst_target_implausible (raw $14.42 vs price $3.22 — ratio 4.5×). Rejected, falling back to technical TP.
Quality below floor (3.7 < 4.0)
Value-trap signals (2/5): Margin compression (op margin -8.1%), Material insider selling (21 sells, 5.70% of cap)

Key Metrics

P/E (TTM)—
P/E (Fwd)-4.5
Mkt Cap$770M
EV/EBITDA-4.9
Profit Mgn0.0%
ROE-989.1%
Rev Growth-76.7%
Beta0.97
DividendNone
Analysts with ratings16

Quality Signals

Piotroski F3/9

Options Flow

P/C0.20bullish

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.0
Growth Rank
0.7
Value Rank
5.0

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Volume
1.9
Macd
3.0
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA, MA slope -5.9%/30d — confirmed downtrend

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roa
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Piotroski F
3.3
Moat
4.0
Current Ratio
9.2
Gross Margin
10.0
Cash-burning: FCF -4728% of revenueNo competitive moatRule of 40: -4805 (fail)Weak Piotroski F-Score: 3/9
GatesMomentum 2.1<4.5Death cross (50MA < 200MA)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 134d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Speculative
RSI
38 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $3.10Resistance $4.27

Price Targets

$3
$4
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $14.42 vs price $3.22 — ratio 4.5×). Rejected, falling back to technical TP.
! Quality below floor (3.7 < 4.0)
! Value-trap signals (2/5): Margin compression (op margin -8.1%), Material insider selling (21 sells, 5.70% of cap)

Earnings

B
B
B
M
3/4 beats
Next Earnings2027-04-01 (134d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is IVA stock a buy right now?

Sell if holding. Engine safety override at $3.22: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $3.01. Score 4.7/10, moderate confidence.

What is the IVA stock price target?

Resistance target: $4.18 (+29.8% upside). Prior stop was $3.01. Stop-loss: $3.01.

What are the risks of investing in IVA?

DATA_ISSUE: analyst_target_implausible (raw $14.42 vs price $3.22 — ratio 4.5×). Rejected, falling back to technical TP.; Quality below floor (3.7 < 4.0); Value-trap signals (2/5): Margin compression (op margin -8.1%), Material insider selling (21 sells, 5.70% of cap).

Is IVA overvalued or undervalued?

Inventiva S.A. - American Depos trades at a P/E of N/A (forward -4.5). TrendMatrix value score: 5.0/10. Verdict: Sell.

What do analysts say about IVA?

16 analysts rate IVA, with a consensus score of 4.4/5. 12 analysts publish price targets averaging $14.

What does Inventiva S.A. - American Depos do?Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies...

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · MGTX (MeiraGTx Holdings plc) · HRMY (Harmony Biosciences Holdings, I) · CORT (Corcept Therapeutics Incorporat)
Home › Stocks › IVA

Latest news

Latest News

The Globe and Mail63d agoAnalyst
The Globe and Mail60d agoAnalyst
Reuters60d ago
DirectorsTalk Interviews61d agoAnalyst
Fiscal.ai13d agoAnalyst
Benzinga13d agoAnalyst
Fiscal.ai25d agoAnalyst
Benzinga47d agoAnalyst
Benzinga48d ago
Benzinga48d ago
Benzinga48d ago
Benzinga49d ago
Benzinga50d ago
Benzinga50d ago
Benzinga51d agoEarnings
Benzinga51d agoEarnings
Benzinga51d ago
Benzinga54d agoEarnings
Benzinga58d ago
Benzinga77d agoProduct
Loading more...